文献速递白血病

口服地西他滨/西达尿苷对比静脉地西他滨治疗急性髓系白血病:一项随机、交叉、注册药代动力学研究

Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
PubMed 文献 · Br J Haematol · 2024-09-23

该研究在89例不适合强化诱导化疗的急性髓系白血病(AML)患者中,比较静脉地西他滨(DEC-IV,20 mg/m2,5天)与口服地西他滨/西达尿苷(DEC-C)的地西他滨暴露量、临床疗效和安全性。结果显示两种制剂5天药时曲线下面积比值为99.64(90%CI 91.23%, 108.80%),去甲基化率差异≤1.1%,口服DEC-C的中位总生存期、临床反应和安全性特征与既往DEC-IV观察结果一致。

要点

  • 口服DEC-C与静脉DEC-IV的地西他滨全身暴露量等效(AUC比值99.64,90%CI 91.23%–108.80%)。
  • 两种制剂去甲基化率相似,差异≤1.1%。
  • 口服DEC-C的中位总生存期、临床反应和安全性特征与既往DEC-IV观察结果一致。

核心结论

  • 研究结果支持在急性髓系白血病患者中使用口服DEC-C。
  • TP53突变与不良结局相关。

研究设计与样本

  • 随机、交叉、注册药代动力学研究,89例不适合强化诱导化疗的急性髓系白血病患者按1:1随机分配至DEC-IV组或口服DEC-C组。
  • DEC-IV剂量为20 mg/m2,5天;DEC-C为口服地西他滨联合西达尿苷,28天治疗周期中第1–5天给药。
  • 第一周期后交叉,下一周期接受另一种制剂5天,随后所有患者继续口服DEC-C治疗直至停药。

主要发现

  • 两种地西他滨制剂5天药时曲线下面积比值为99.64(90%CI 91.23%, 108.80%)。
  • 去甲基化率差异≤1.1%。
  • 口服DEC-C的中位总生存期、临床反应和安全性特征与既往DEC-IV观察结果一致。
  • 通过下一代测序识别影响总生存期的分子异常,TP53突变与不良结局相关。

关键数值与推荐

  • DEC-IV剂量为20 mg/m2,5天。
  • DEC-C在28天治疗周期的第1–5天口服给药。
  • 两种制剂5天药时曲线下面积比值99.64(90%CI 91.23%, 108.80%)。
  • 去甲基化率差异≤1.1%。

临床怎么用

  • 原文结论支持在急性髓系白血病患者中使用口服DEC-C。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study compared decitabine exposure when administered IV (DEC-IV) at a dose of 20 mg/m2 for 5-days with orally administered decitabine with cedazuridine (DEC-C), as well as the clinical efficacy and safety of DEC-C in patients with acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. In all, 89 patients were randomised 1:1 to DEC-IV or oral DEC-C (days 1-5 in a 28-day treatment cycle), followed by 5 days of the other formulation in the next treatment cycle. All patients received oral DEC-C for subsequent treatment cycles until treatment discontinuation. Equivalent systemic decitabine exposures were demonstrated (5-day area under the curve ratio between the two decitabine formulations of 99.64 [90% confidence interval 91.23%, 108.80%]). Demethylation rates also were similar (≤1.1% difference). Median overall survival (OS), clinical response and safety profile with oral DEC-C were consistent with those previously observed with DEC-IV. Next-generation sequencing was performed to identify molecular abnormalities that impact OS and TP53 mutations were associated with a poor outcome. These findings support the use of oral DEC-C in patients with AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Geissler K, Koristek Z, Del Castillo TB, et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. Br J Haematol. 2024. PMID: 39313917. doi:10.1111/bjh.19741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。